Eterna Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.070
+0.030 (2.88%)
At close: Nov 4, 2024, 4:00 PM
1.120
+0.050 (4.66%)
After-hours: Nov 4, 2024, 4:02 PM EST

Company Description

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies.

Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system.

The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Eterna Therapeutics Inc.
Eterna Therapeutics logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Sanjeev Luther

Contact Details

Address:
1035 Cambridge Street, Suite 18A
Cambridge, Massachusetts 02141
United States
Phone 212 582 1199
Website eternatx.com

Stock Details

Ticker Symbol ERNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000748592
CUSIP Number 114082209
ISIN Number US1140822099
Employer ID 31-1103425
SIC Code 2834

Key Executives

Name Position
Sanjeev Luther Chief Executive Officer, President and Director
Sandra M. Gurrola Principal Financial and Accounting Officer and Senior Vice President of Finance
Dr. Robert Hamilton Pierce M.D. Chief Scientific Officer
Dorothy J. Clarke General Counsel and Director

Latest SEC Filings

Date Type Title
Oct 29, 2024 8-K Current Report
Oct 16, 2024 ARS Filing
Oct 7, 2024 DEF 14A Other definitive proxy statements
Sep 27, 2024 PRE 14A Other preliminary proxy statements
Sep 27, 2024 8-K Current Report
Sep 25, 2024 8-K Current Report
Sep 23, 2024 8-K Current Report
Aug 19, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
May 14, 2024 10-Q Quarterly Report